Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID‐19

Luca Steardo,Luca Steardo,Robert Zorec,Alexei Verkhratsky
DOI: https://doi.org/10.1111/apha.13473
IF: 7.523
2020-04-11
Acta Physiologica
Abstract:The new coronavirus, classified as severe acute respiratory syndrome (SARS)‐CoV‐2 that emerged in Hubei province in China, causes a new coronavirus disease, which was termed COVID‐19 by WHO on 11 February 2020. COVID‐19 claimed more than 65 000 lives around the world by 5th of April 2020. It is not the first coronavirus, which infects humans; the pathogenic viruses that cause human diseases (human coronaviruses, HCoV) include 6 other members designated as SARS‐CoV, middle east respiratory syndrome (MERS)‐CoV, HCoV‐HKU1, HCoV‐NL63, HCoV‐OC43 and HCoV‐229E. The clinical presentation is mainly manifested as malignant pneumonia; although many patients present neurological symptoms, such as vomiting, dizziness, headache and delirium.1 Human coronaviruses were first identified in the mid‐1960s; they were named for the crown‐like spikes on their surface. The SARS‐CoV‐2 virus belongs to β‐coronavirus, which also include MERS‐CoV, SARS‐CoV‐1, NCoV‐OC43 and HCoV‐HKU1. The primary target cells for SARS‐CoV‐2 are the epithelial cells of the respiratory and gastrointestinal tract, which contain angiotensin converting enzyme 2 (ACE2), that is utilized by the virus to enter the cell; it is, however, hard to believe that the penetration of the viral agent into the organism is limited only to these tissues.2
physiology
What problem does this paper attempt to address?